Chronic inflammation remains a major unmet need, with two novel programs—EVO756 and EVO301—advancing through Phase 2 trials targeting atopic dermatitis and migraine. Both candidates show strong efficacy and safety, supported by a robust financial position and experienced leadership.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.